DENVER--(BUSINESS WIRE)--Aug. 7, 2006--Myogen, Inc. (Nasdaq:MYOG - News), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today reported 2006 second quarter results. As of June 30, 2006, the Company had cash, cash equivalents and investments of $188.1 million. Loss from continuing operations for the quarter ended June 30, 2006, was $18.5 million, or $0.44 per share, compared to a loss from continuing operations of $21.7 million, or $0.61 per share during the same period last year. Loss from continuing operations for the six months ended June 30, 2006, was $36.1 million, or $0.85 per share, compared to a loss from continuing operations of $40.3 million, or $1.13 per share during the same period last year.
